Literature DB >> 6134620

Long-term alpha-adrenergic-blocking therapy in detrusor-urethra dyssynergia.

R L Vereecken, H Van Poppel, G Boeckx, A Leruitte.   

Abstract

Neurogenic dyssynergia was treated with alpha-adrenergic blockers. Only 21 of 43 highly selected patients with residual urines and low flow rates continued therapy with phenoxybenzamine for more than 6 months, despite initial benefits. The causes of therapy discontinuation are discussed. A combination of 5 mg dibenzylin, 3 times daily, with parasympathomimetic drugs is often necessary. The mechanisms of action of alpha-adrenergic-blocking agents are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134620     DOI: 10.1159/000474074

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Is There a Role for alpha-Blockers for the Treatment of Voiding Dysfunction Unrelated to Benign Prostatic Hyperplasia?

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2005

2.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 3.  Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis)

Authors:  C J Fowler; P E van Kerrebroeck; A Nordenbo; H Van Poppel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.